Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T for R/R CD7+ T-cell Lymphoma and Acute Leukemia
NCT07008872Not yet recruiting
- Sponsor
- Qideng Pharmaceutical
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Autologous CAR-T
01
Overview
Open-label trial of CD7 CAR-T cells injection in T-cell lymphoma, t-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML), sponsored by Qideng Pharmaceutical. Primary endpoints: Safety of CD7 CAR-T cell therapy at 1 month and Efficacy of CD7 CAR-T cell therapy at 3 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
CD7 CAR-T cells injection
03
Conditions
T-cell lymphomat-cell acute lymphoblastic leukemia (T-ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07008872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008872.